Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Stomach Neoplasms × bemarituzumab × Clear all

Phase

Phase 3 2 Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Ovarian Neoplasms 1 Endometrial Neoplasms 1

Interventions

pembrolizumab 23 Paclitaxel 22 Oxaliplatin 16 Nivolumab 15 Capecitabine 13 Docetaxel 12 Cisplatin 12 S 1 (combination) 10 Irinotecan 9 Fluorouracil 8 Cyclophosphamide 8 Carboplatin 8 fludarabine 7 Trastuzumab 7 tislelizumab 6 aldesleukin 5 Ramucirumab 5 Drug Therapy 5 apatinib 4 Radiotherapy 4 Leucovorin 4 Interleukin-2 4 Gemcitabine 4 Bevacizumab 4 sintilimab 3 regorafenib 3 olaparib 3 Pemetrexed 3 Ipilimumab 3 Immunotherapy, Adoptive 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322577 2025-12-05

FORTITUDE-103

Amgen

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡